Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 6, 2013
Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignanciesG S Patel, K Jain, R Kumar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive careT R Asmis, E Powell, C S Karapetis, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2015
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17S Y Brulé, D J Jonker, C S Karapetis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 28, 2015
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot studyJ M Bowen, I White, L Smith, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2016
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancerD Ferraro, D Goldstein, R L O'Connell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancerJ Tie, I Kinde, Y Wang, et al.
The Pharmacogenomics Journal|April 9, 2014
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.
British Journal of Cancer|December 17, 2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancerD J Jonker, C S Karapetis, C Harbison, et al.
British Journal of Cancer|February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD databaseC S Karapetis, H Liu, M J Sorich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2012
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17M M Vickers, C S Karapetis, D Tu, et al.
Pageof 4